









Markets
/
Stocks
/
nasdaq-mbio
/

Mustang Bio Inc

MBIO

0.725USD

+0.002+0.29%

Market hours （ET）Quotes delayed by 15 min

25.35KMarket Cap

LossP/E TTM



Mustang Bio Inc

0.725

+0.002+0.29%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Mustang Bio Inc

Currency: USD Updated: 2026-03-27

Key Insights

Mustang Bio Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 229 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is very high.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Mustang Bio Inc's Score

Industry at a Glance

Industry Ranking

229 / 391

Overall Ranking

488 / 4542

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Mustang Bio Inc Highlights

StrengthsRisks

Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on translating medical breakthroughs into potential cures for cancers and autoimmune diseases. The Company has partnered with medical institutions to advance the development of chimeric antigen receptor modified T cell (CAR T) therapies. Its pipeline is focused in two core areas: CAR T therapies for autoimmune diseases and hematologic malignancies and CAR T therapies for solid tumors. It is developing a CAR T therapy for hematologic malignancies and autoimmune diseases in partnership with Fred Hutchinson Cancer Center targeting CD20 and for solid tumors in partnership with City of Hope National Medical Center targeting IL13Ra2. It has also partnered with Nationwide Children’s Hospital for a herpes simplex virus type 1 oncolytic virus to enhance the activity of MB-101 for the treatment of patients with high-grade malignant brain tumors.

Undervalued

The company’s latest PE is -1.85, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 296.11K shares, increasing 12.47% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 57.86K shares of this stock.

Analyst Rating

Based on 0 analysts

Current Rating

Target Price

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-03-27

The current financial score of Mustang Bio Inc is 7.56, ranking 82 out of 391 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

7.56

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

10.00

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

4.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.03

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Mustang Bio Inc's Company Valuation

Currency: USD Updated: 2026-03-27

The current valuation score of Mustang Bio Inc is 8.39, ranking 47 out of 391 in the Biotechnology & Medical Research industry. Its current P/E ratio is -1.85, which is -99.97% below the recent high of -0.00 and -17.97% above the recent low of -2.18.

Score

Industry at a Glance

Previous score

8.39

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 229/391

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-03-27

No earnings forecast score is currently available for Mustang Bio Inc. The Biotechnology & Medical Research industry's average is 8.07.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-03-27

The current price momentum score of Mustang Bio Inc is 1.36, ranking 385 out of 391 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 0.93 and the support level at 0.61, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

1.34

Change

0.02

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.040

Sell

RSI(14)

26.769

Sell

STOCH(KDJ)(9,3,3)

7.268

Oversold

ATR(14)

0.065

Low Volatility

CCI(14)

-129.548

Sell

Williams %R

94.748

Oversold

TRIX(12,20)

-0.658

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

0.770

Sell

MA10

0.823

Sell

MA20

0.885

Sell

MA50

0.920

Sell

MA100

1.045

Sell

MA200

1.342

Sell

Institutional Confidence

Currency: USD Updated: 2026-03-27

The current institutional shareholding score of Mustang Bio Inc is 3.00, ranking 195 out of 391 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 4.59%, representing a quarter-over-quarter increase of 119.55%. The largest institutional shareholder is The Vanguard, holding a total of 57.86K shares, representing 0.86% of shares outstanding, with 1.00% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Fortress Biotech Inc

257.53K

-0.26%

Kestra Advisory Services, LLC

66.11K

BlackRock Institutional Trust Company, N.A.

84.73K

+5026.01%

The Vanguard Group, Inc.

Star Investors

57.86K

Geode Capital Management, L.L.C.

26.42K

+64.27%

XTX Markets LLC

18.77K

Risk Assessment

Currency: USD Updated: 2026-03-27

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. No risk assessment score is currently available for Mustang Bio Inc. The Biotechnology & Medical Research industry's average is 3.38. The company's beta value is 2.18. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.